期刊文献+

非酒精性脂肪性肝病的治疗 被引量:10

Therapeutics of non-alcoholic fatty liver disease
原文传递
导出
摘要 非酒精性脂肪性肝病(NAFLD)及其主要类型一非酒精性脂防性肝炎(NASH),不仅是肝酶持续异常的首要病因,而且可导致失代偿期肝硬化、肝细胞癌以及肝衰竭。随着亚洲地区肥胖症和糖尿病患者的不断增多,近期NAFLD或NASH的患病率仍将不断攀升并呈现出低年龄化的发病趋势。为此,亚太地区NAFLD工作组起草了NAFLD诊疗指南,无疑这将对本地区NAFLD的诊断和治疗起到重要指导作用。
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2007年第9期687-688,共2页 Chinese Journal of Hepatology
关键词 脂肪肝 治疗学 Fatty liver Therapeutics
  • 相关文献

参考文献7

  • 1Fan JG, Saibara T, Chitturi S, et al. What are the risk factors and settings for non-alcoholic fatty liver disease in Asia-Pacific? J Gastroenterol Hepatol, 2007, 22: 794-800.
  • 2Farrell GC, Chitturi S, Lau GK, et al. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia- Pacific region: Executive summary. J Gastroenterol Hepatol, 2007, 22: 775-777.
  • 3Chitturi S, Farrell GC, Hashimoto E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region: Definitions and overview of proposed guidelines. J Gastroenterol Hepatol, 2007, 22: 778-787.
  • 4Chan HL, de Silva HJ, Leung NW, et al. How should we manage patients with non-alcoholic fatty liver disease in 2007? J Gastroenterol Hepatol, 2007, 22:801-808.
  • 5Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and ale there local differences? J Gastroenterol Hepatol, 2007, 22:788- 793.
  • 6Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology, 2005, 41: 690-695.
  • 7Cohen DE, Anania FA, Chalasani N, et al. An assessment of statin safety by hepatologists. Am J Cardiol, 2006,97(8A): 77C-81C.

同被引文献135

引证文献10

二级引证文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部